ArticleJournal of the American Heart Association2025
Comparative Risk of Atrial Fibrillation Onset in Statin-Treated Patients Initiating Icosapent Ethyl and Omega-3 Acid Ethyl Esters: A Retrospective Cohort Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIcosapent ethyl (IPE) and omega-3-acid ethyl esters (docosahexaenoic acid [DHA]/eicosapentaenoic acid [EPA]) are approved as adjunct therapies to statins for reducing cardiovascular events in at-risk patients. However, concerns remain regarding a potential link between IPE and atrial fibrillation (AF). We compared the risk of AF onset in patients who initiated IPE versus DHA/EPA as adjuncts to statin therapy.
methodsWe conducted a retrospective cohort study using the Merative MarketScan Commercial Claims and Medicare Supplemental database in the United States. An active-comparator, new-user study design was applied. Adults diagnosed with dyslipidemia and receiving statin therapy who initiated IPE or DHA/EPA between January 2013 and June 2021 were identified. A propensity score-matched cohort was created using baseline demographic characteristics, comorbidities, and medication dispensing records, with exact matching on therapy initiation period. Patients were followed for up to 2 years while they were on IPE or DHA/EPA therapy to identify incident AF. Cumulative incidence was estimated using Kaplan-Meier methods, and risks between groups were compared using Cox proportional hazards analysis.
resultsThe propensity score-matched cohort included 17 635 participants, with a mean age of 55 years, and was predominantly men (65.4%). Over 2 years, the cumulative incidence of AF from IPE and DHA/EPA was 5.20% (95% CI, 4.62%-5.84%) and 4.07% (95% CI, 3.58%-4.62%) respectively, resulting in a hazard ratio of 1.21 (95% CI, 1.03-1.42).
conclusionsThese findings suggest that, in adult patients who are AF naïve, IPE may be associated with a higher risk of AF compared with DHA/EPA when used as add-on therapy with statins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.